Affiliation:
1. Comenius University in Bratislava, Jessenius Faculty of Medicine and University Hospital in Martin, Department of Pathological Anatomy, Slovakia
2. Martin s Biopsy Center, Ltd in Martin, Slovakia
Abstract
Abstract
Myelodysplastic syndrome (MDS) represent very heterogenous group of clonal stem cell bone marrow disorders with ineffective haematopoesis leading to cytopenias in peripheral blood and increased risk of blastic transformation and evolution of acute myeloid leukemia. MDS is a disease of older age mostly, in children it seems to be very rare. There are several significant morphological, cytogenetic and prognostic differencies of the disease in adults and in children. Adult MDS patients most commonly manifest with symptoms of anemia, bleeding and infection are uncommon. In childhood, MDS manifests predominantly by neutropenia and thrombocytopenia. In addition, some pediatric MDS patients present also with constitutional disease’s signs and symptoms. Early and correct diagnosis in both age groups is essential for the choice of appropriate therapy and also for next life of patients. However, the diagnosis of MDS is challenging, complex and requiring close correlation of clinical symptoms, laboratory parameters and standardized examination of BM biopsies. The authors present an overview focused on biology of MDS in adults and children, on the differences in the incidence, clinical presentation and treatment. They summarize the possibilities and limits of histopathological diagnosis and differential diagnosis of the disease in different age groups. A major problem in the morphological diagnosis of MDS remains the determination, whether the myelodysplasia is due to clonal disorder. It might result also from some other factors, as significant dysplasia can also occur in reactive conditions, and vice versa, only discrete dysplasia is sometimes observed in MDS patients. Although histomorphological and immunohistochemical analysis of BM biopsy is invasive and time-consuming examination, it has its value in the diagnosis, differential diagnosis and evaluation of therapeutic effect.
Subject
General Biochemistry, Genetics and Molecular Biology,General Nursing
Reference43 articles.
1. 1. THEPOT S., BOEHRER S., SEKERES V. et al. (2014). A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leuk Res 38: 1430-1434
2. 2. RANKIN E. B., NARLA A., PARK J. K. et al. (2015). Biology of the bone marrow microenvironment and myelodysplastic syndromes. Mol Genet Metab 116: 24-28
3. 3. A DES L., ITZYKSON R., FENAUX P. (2014). Myelodysplastic syndrome. Lancet 383:2239-2252
4. 4. CAZZOLA M., DELLA PORTA M. G, TRAVAGLINO E. et al. (2011). Classification and Prognostic Evaluation of Myelodysplastic Syndromes. Semin Oncol 38 (5): 627-634
5. 5. SWERDLOW S. H., CAMPO E., HARRIS N.L. et al. (2008). World Health Organization Classification of Tumours of Hematopoetic and Lymphoid Tissues. 4th Edition. Lyon: IARC Press 2008: 86-103.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Pediatric myelodysplastic syndrome;Seminars in Diagnostic Pathology;2023-05